Evidence map›Paper›PMID 24458472›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2014

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

R Leibowitz-Amit, A J Templeton, A Omlin, C Pezaro, E G Atenafu, D Keizman, F Vera-Badillo, J-A Seah, G Attard, J J Knox and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Prostate carcinogenesis: inflammatory storms.Nature reviews. Cancer · 2020
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

R Leibowitz-AmitDepartments of Medical Oncology and Haematology.
A J TempletonDepartments of Medical Oncology and Haematology.
A OmlinProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
C PezaroProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
E G AtenafuBiostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
D KeizmanGenitourinary Oncology Service, Meir Medical Center, Kfar-Saba, Israel.
F Vera-BadilloDepartments of Medical Oncology and Haematology.
J-A SeahDepartments of Medical Oncology and Haematology.
G AttardProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
J J KnoxDepartments of Medical Oncology and Haematology.
S S SridharDepartments of Medical Oncology and Haematology.
I F TannockDepartments of Medical Oncology and Haematology.
J S de BonoProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
A M JoshuaDepartments of Medical Oncology and Haematology. Electronic address: anthony.joshua@uhn.ca.
Royal Marsden NHS Foundation Trust · GBMeir Medical Center · ILPrincess Margaret Cancer Centre · CASt. Anthony’s Hospital · US

Funding

Cancer Research UK 13239
6 · The paper itself

Abstract

backgroundAbiraterone acetate (abiraterone) prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). This study's objective was to retrospectively identify factors associated with prostate-specific antigen (PSA) response to abiraterone and validate them in an independent cohort. We hypothesized that the neutrophil/lymphocyte ratio (NLR), thought to be an indirect manifestation of tumor-promoting inflammation, may be associated with response to abiraterone. PATIENTS AND

methodsAll patients receiving abiraterone at the Princess Margaret (PM) Cancer Centre up to March 2013 were reviewed. The primary end point was confirmed PSA response defined as PSA decline ≥50% below baseline maintained for ≥3 weeks. Potential factors associated with PSA response were analyzed using univariate and multivariable analyses to generate a score, which was then evaluated in an independent cohort from Royal Marsden (RM) NHS foundation.

resultsA confirmed PSA response was observed in 44 out of 108 assessable patients (41%, 95% confidence interval 31%-50%). In univariate analysis, lower pre-abiraterone baseline levels of lactate dehydrogenase, an NLR ≤ 5 and restricted metastatic spread to either bone or lymph nodes were each associated with PSA response. In multivariable analysis, only low NLR and restricted metastatic spread remained statistically significant. A score derived as the sum of these two categorical variables was associated with response to abiraterone (P = 0.007). Logistic regression analysis on an independent validation cohort of 245 patients verified that this score was associated with response to abiraterone (P = 0.003). It was also associated with OS in an exploratory analysis.

conclusionsA composite score of baseline NLR and extent of metastatic spread is associated with PSA response to abiraterone and OS. Our data may help understand the role of systemic inflammation in mCRPC and warrant further research.

Indexed as

Abiraterone AcetateAgedAged, 80 and overAndrogen AntagonistsAndrostadienesBiomarkers, TumorDisease-Free SurvivalDisease ProgressionHumansKallikreinsL-Lactate DehydrogenaseLymphocytesMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisAbiraterone AcetateAndrogen AntagonistsAndrostadienesBiomarkers, TumorKallikreinsKLK3 protein, humanL-Lactate DehydrogenasePrednisoneProstate-Specific AntigenSteroid 17-alpha-Hydroxylaseabiraterone acetatemCRPCNLRprostate cancerresponse

Identifiers

PMID24458472
PMCPMC4433513
OpenAlexW2119034557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.